"Altimmune's New Weight-Loss Drug Minimizes Muscle Loss and Mimics Exercise Effects"

TL;DR Summary
Altimmune has developed a new GLP-1 drug, pemvidutide, which helps patients lose 75% fat and only 25% muscle, unlike existing drugs like Ozempic and Mounjaro, which can lead to significant muscle loss. The drug combines a GLP-1 drug with another to mimic the effects of exercise, potentially offering a solution to the issue of muscle loss while on weight-loss medication. Other drugmakers, such as Eli Lilly, are also working on solutions to preserve muscle mass in patients using similar drugs.
- New GLP-1 weight-loss drug mimics effects of exercise with a shot Business Insider
- Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart CNBC
- Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place (NASDAQ:ALT) Seeking Alpha
- Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial Bloomberg
- Altimmune's Weight Loss Drug Minimized Muscle Mass Loss Forbes
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
82%
446 → 80 words
Want the full story? Read the original article
Read on Business Insider